|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors显示文摘Somatostatin analogs were initially developed for the control of hormonal syndromes associated with neuro-endocrine tumors (NETs). In recent years, accumul ating data has supported their role as antiproliferative agents, capable of stabilizing tumor growth in patients with metastatic neuroendocrine malignancies, including carci-noid and pancreatic endocrine tumors. A phase Ⅲ, ran-domized, placebo-controlled trial has now demonstrated that octreotide long-acting repeatable (LAR) 30 mg can significantly prolong time to tumor progression among patients with metastatic midgut NETs regardless of functional status, chromogranin A level or age. In addition to signif icantly lengthening time to tumor pro-gression in the overall study population, subset analysis suggests that patients with low tumor burden are most likely to experience disease stabilization with octreotide LAR 30 mg, supporting the early use of octreotide LAR in patients with metastatic disease. Further research efforts are underway to evaluate the use of somatostatin analogs as antiproliferative agents in other types of gastroenteropancreatic-NETs. Ongoing studies are also evaluating novel somatostatin analogs and somatostatin analogs in combination with other anti-tumor therapies. | Jonathan Strosberg Larry Kvols | 2010 | World Journal of Gastroenterology2010，16，24： | 10 |
| 2 | Survival and response after peptide receptor radionuelide therapy with octreotide in patients with advanced gastroenteropancreatie neuroendocrine tumors显示文摘 | Valkema R Pauwels S Kvols LK | 2006 | Semin Nucl Med2006，36，2： | 1 |
| 3 | Treatment of neuroendocrine carcinomas with c, ombined etoposide and cisplatin显示文摘 | Moertel CG Kvols LK O'Connell M J el al | 1991 | Cancer1991，68，2： | 1 |
| 4 | Phase 1 study of therapy with ^90Y-SMT487 (Octreo Ther) in patients with somatostatin receptor-positive tumors显示文摘 | Vakema R Kvols L Jamar F Bakker WH Smith C Krenning EP Pauwels S | 2002 | J Nucl Med2002，43，： | 1 |
| 5 | Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors 显示文摘 | KVOLS L K WOUFERING E A | 2006 | Anticancer Drugs2006，17，6： | 1 |
| 6 | Cytoreductive hepatic surgery for neuroendocrine tumors显示文摘 | McEntee GP Nagorney DM Kvols LK | | 0，，： | 1 |
| 7 | Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut显示文摘 | Strosberg J Gardner N Kvols L | | 0，，04： | 1 |
| 8 | Distribution of somatostantin receptors in normal and tumor tissue 显示文摘 | Reubi JC Kvols L Krenning E | 1990 | Metabolism1990，39，2： | 1 |
| 9 | A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract 显示文摘 | Strosberg JR Cheema A Kvols LK | 2011 | Cancer Control2011，18，2： | 1 |
| 10 | Phase Ⅱ proof-ofconcept study of atiprimod in patients with advanced low-to intermediate-grade neuroendocrine carcinoma显示文摘 | Sung MW Kvols L Wolin E | 2008 | J Clin Oncol2008，，： | 1 |
| 11 | Survival and prognostic factor analysis of 146 metastatic neuroendoerine tumors of the mid-gut 显示文摘 | Strosberg J Gardner N Kvols L | 2009 | Neuroendocrinology2009，89，4： | 1 |
| 12 | Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut 显示文摘 | Strosberg J Gardner N Kvols L | 2009 | Neuroendocrinology2009，89，4： | 1 |
| 13 | Distribution of somatostatinrecptors in normal and tumor tissue显示文摘 | Rcubi JC Kvols L Krenning EP | 1990 | Metabolism1990，39，2： | 1 |
| 14 | Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer显示文摘 | Gunderson LL Martin JK Kvols LT | 1987 | Int J Radiat Oncol Biol Phys1987，13，3： | 1 |
| 15 | Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut 显示文摘 | Strosberg J Gardner N Kvols L | 2009 | Neuroendocrinology2009，89，4： | 1 |
| 16 | Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate 显示文摘 | Valkema R Pauwels SA Kvols LK | 2005 | J Nucl Med2005，46，1： | 1 |
| 17 | Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut显示文摘 | Strosberg J Gardner N Kvols L | 2009 | Neuroendocrinology2009，89，4： | 1 |
| 18 | Metastatic cancer to the testes:A report of 20cases and review of the literature显示文摘 | Patel S R Richardson R L Kvols L | 1989 | J Urol1989，142，4： | 1 |
| 19 | Phase II study of 5-fluorouracil,doxorubicin,and mitomycin C for metastatic small bowel adenocarcinoma显示文摘 | Gibson MK Holcroft CA Kvols LK | 2005 | Oncologist2005，10，2： | 1 |
| 20 | Cytoreductive hepatic surgery for neuroendocrine tumors显示文摘 | McEntee GP Nagorney DM Kvols LK | | 0，，06： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员